COVID-19: Implementation of clinical decision support systems to support oncology care teams in their decision-making.
Containment measures related to COVID-19 as well as prioritization of healthcare resources to help fight this pandemic and provide care for hospitalized infected patients has led healthcare providers to cancel or delay necessary surgeries and other procedures, including screening, chemotherapy and radiation therapy.
Clinical decision support systems can integrate patient data and findings from imaging, pathology, lab and genomic testing to facilitate diagnostic and treatment decisions. One of them is the NAVIFY™ Tumor Board from Roche Diagnostics.
The NAVIFY™ Tumor Board solution is a cloud-based workflow solution that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology multidisciplinary care teams to review, align and decide rapidly on the optimal treatment for the patient.
Over 15 countries have successfully implemented it at multiple hospitals worldwide, including the University of Missouri School of Medicine (MU School of Medicine) and the Hospital del Mar in Spain. NAVIFY™ Tumor Board is currently in the testing phase at two Canadian hospitals.
Findings from a recent study indicate that a digital tumor board solution could have a significant impact on the amount of time spent preparing for multidisciplinary team meetings. They also demonstrated a reduction in preparation time variability. Digital tools ensure availability of all required data, increase efficiency of therapy decision-making, and lead to higher throughput of cases resulting in shorter time-to-treatment.
Considering the current backlog in cancer patients awaiting surgeries, minimizing upfront work lets teams focus on individualized treatment decisions, reviewing, determining, and better managing care.
